Available online at www.sciencedirect.com
Psychiatry Research 165 (2009) 201 – 214
www.elsevier.com/locate/psychres
Review
Pathophysiology of depression: Role of sleep and
the melatonergic system
Venkataramanujan Srinivasan a,1 , Seithikurippu R. Pandi-Perumal b,⁎, Ilya Trakht b ,
D.Warren Spence c , Ruediger Hardeland d , Burkhard Poeggeler d , Daniel P. Cardinali e
a
Department of Physiology, School of Medical Sciences, University Sains Malaysia, Kubang Kerian, Kota Bharu, Kelantan, Malaysia
b
Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine,
College of Physicians and Surgeons of Columbia University, 630 West 168th Street- Rm # BB813, New York, NY 10032, USA
c
Sleep and Alertness Clinic, 750 Dundas Street West, Toronto, Canada ON M6J-3S3
d
Johann Friedrich Blumenbach Institute of Zoology and Anthropology, University of Goettingen, D-37073 Goettingen, Germany
e
Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155. 1121 Buenos Aires, Argentina
Received 22 June 2007; received in revised form 13 September 2007; accepted 12 November 2007
Abstract
Profound disturbances in sleep architecture occur in major depressive disorders (MDD) and in bipolar affective disorders. Reduction
in slow wave sleep, decreased latency of rapid eye movement (REM) sleep and abnormalities in the timing of REM/non-REM sleep
cycles have all been documented in patients with MDD. It is thus evident that an understanding of the basic mechanisms of sleep
regulation is essential for an analysis of the pathophysiology of depressive disorders. The suprachiasmatic nucleus (SCN), which
functions as the body's master circadian clock, plays a major role in the regulation of the sleep/wakefulness rhythm and interacts actively
with the homeostatic processes that regulate sleep. The control of melatonin secretion by the SCN, the occurrence of high concentrations
of melatonin receptors in the SCN, and the suppression of electrical activity in the SCN by melatonin all underscore the major influence
which this neurohormone has in regulating the sleep/wake cycle. The transition from wakefulness to high sleep propensity is associated
with the nocturnal rise of endogenous melatonin secretion. Various lines of evidence show that depressed patients exhibit disturbances in
both the amplitude and shape of the melatonin secretion rhythm and that melatonin can improve the quality of sleep in these patients. The
choice of a suitable antidepressant that improves sleep quality is thus important while treating a depressive disorder. The novel
antidepressant agomelatine, which combines the properties of a 5-HT2C antagonist and a melatonergic MT1/MT2 receptor agonist, has
been found very effective for resetting the disturbed sleep/wake cycle and in improving the clinical status of MDD. Agomelatine has also
been found useful in treating sleep problems and improving the clinical status of patients suffering from seasonal affective disorder.
© 2007 Elsevier Ireland Ltd. All rights reserved.
Keywords: Depression; Sleep; Melatonin; Agomelatine; Suprachiasmatic nucleus; Chronobiotics; Seasonal affective disorder
Contents
1.
2.
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202
Prevalence of sleep disorders in depression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203
⁎ Corresponding author. Tel: +1 917 455 7147; fax: +1 212 342 2969.
E-mail address: sleepresearch@gmail.com (S.R. Pandi-Perumal).
1
Current address for V. Srinivasan is: Prof. of Physiology, SRM Medical College & Research Centre SRM University Kattankulathoor -603203
Kancheepuram District INDIA.
0165-1781/$ - see front matter © 2007 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.psychres.2007.11.020
202
V. Srinivasan et al. / Psychiatry Research 165 (2009) 201–214
3. Sleep changes as markers for depression . . . . . . . . . . . . . . . . . . . . . . . .
4. Physiology of sleep regulatory mechanisms: role of the melatonergic system . . . . .
5. Regulation of melatonin secretion by the SCN . . . . . . . . . . . . . . . . . . . . .
6. Melatonin's role in the regulation of sleep . . . . . . . . . . . . . . . . . . . . . . .
7. Melatonin in MDD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8. Antidepressants and sleep: role of the novel melatonergic antidepressant agomelatine .
9. Agomelatine in sleep disturbances of SAD . . . . . . . . . . . . . . . . . . . . . . .
10. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1. Introduction
According to the World Health Organization, depression affects nearly 121 million people worldwide. It is
also one of the top 10 causes of morbidity and mortality
(Rosenzweig-Lipson et al., 2007). Depression is a
heterogeneous syndrome rather than a single disease,
and has been characterized as a collection of “physiological, neuroendocrine, behavioral and psychological
symptoms” (Nestler et al., 2002; Fuchs et al., 2006).
Due to its complexity, many gaps remain in our understanding of the etiology and pathophysiology of depression. However, an increasing amount of evidence is now
pointing to the possibility that chronobiological difficulties may underlie or at least accompany the condition.
Numerous studies undertaken in depressive patients
have suggested that a common comorbidity of depression
is a dysregulation of the circadian timing system. This
seems to occur in various types of depression, but is
particularly evident in bipolar affective disorder (Bunney
et al., 1970; Sitaram et al., 1978; Wehr and Goodwin,
1979).
In nearly 80% of depressed patients, including those
with major depressive disorders (MDD) or bipolar
affective disorder, profound disturbances in sleep architecture have been documented (Wehr and Goodwin,
1979; Reynolds and Kupler, 1988; Armitage and
Hoffmann, 2001). It should be stressed that a marked
overlap exists in the neuronal pathways regulating the
sleep/wake cycle and those presumably altered in depressive illness (Lustberg and Reynolds, 2000). A particular feature of MDD is the abnormality in the timing
and distribution of rapid eye movement (REM) and nonREM (NREM) sleep stages that can be regarded as a
primary characteristic of the disease (Armitage, 2007).
Studies of sleep in depressive and affective disorders
have been useful in supporting theoretical considerations
about their pathophysiology (Srinivasan et al., 2006).
The introduction of tricyclic antidepressants (TCAs)
and monoamine oxidase inhibitors in the 1960s
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
204
204
205
205
206
206
209
209
210
210
prompted a host of studies on the possible neurotransmitter abnormalities in depressed patients. Those studies
demonstrated that functional alterations in brainstem
noradrenergic or serotonergic systems were involved in
both the regulation of mood and affective behaviors and
in the regulation of the sleep/wake cycle. Various
imaging studies (Drevets, 2001; Mayberg, 2003; Berton
and Nestler, 2006) have now shown that several brain
areas such as the prefrontal cortex, cingulate cortex,
hippocampus, striatum, amygdala and thalamus are active during the experience of sleep disorders (insomnia,
fatigue) as well as of disorders of mood (including
depressed mood, feelings of worthlessness, diminished
ability to concentrate, recurrent thoughts of death or
suicide, as well as other symptoms as per the DSM-IV
criteria for depressive disorders (American Psychiatric
Association, 1994).
Other studies have shown that an increased incidence
of depressive symptoms correlates with poor sleep quality or chronic insomnia, disturbances which appear to be
major risk factors for depression (Lustberg and
Reynolds, 2000). Hence, an understanding of the physiological mechanisms of sleep regulation, and especially of the sequellae of their breakdown can assist in
unraveling the complexities of the pathophysiology of
depressive disorders.
Of particular importance in sleep regulation is the
activity of the hypothalamic suprachiasmatic nucleus
(SCN). The SCN determines the sleep/wake rhythm,
consisting in the timing of sleep propensity and wakefulness, and, further, it helps to consolidate both states
(Borbely, 1982; Edgar et al., 1993; Klerman et al.,
1999; Zee and Manthena, 2007). Inasmuch as neurons
of the SCN express high levels of MT1 and MT2
melatonin receptors (Dubocovich and Markowska,
2005), and, further, since exogenous melatonin has
been shown to depress SCN neuronal activity (Liu et
al., 1997) and to phase-shift the neuronal firing rate
(McArthur et al., 1997), melatonin is assumed to be a
key regulator of the sleep/wakefulness rhythm.
V. Srinivasan et al. / Psychiatry Research 165 (2009) 201–214
203
Fig. 1. The two polysomnograms show the characteristics of healthy sleep (a) in comparison with sleep in a depressed patient (b). (1) In depression, the
period between sleep onset and the first occurrence of REM sleep, shown in gray, is markedly reduced (reduced REM latency). (2) The depressed
patient spend less time in sleep stages 3 and 4 (reduced NREM sleep). (3) In depression, the number of awakenings and arousals is increased and the
patient awakens early in the morning (disturbed sleep continuity). The sleep stages (REM, S1–4, sleep stages 1–4) are given across the time. BM, body
movement; EM, eye movement (reproduced with permission from Nissen, C., Nofzinger, E.A., 2007. Sleep and depression: a functional neuroimaging
perspective, In: Pandi-Perumal, S.R., Ruoti, R.R., Kramer, M. (Eds.), Sleep and Psychosomatic Medicine, Informa Healthcare, London, figure 5.1,
pp. xxiii (color plate).
Moreover, the close association between sleep and
mood disorders suggests that melatonin may also be
important in the regulation of mood (Srinivasan et al.,
2006).
2. Prevalence of sleep disorders in depression
Chronic insomnia is considered to be one of the most
frequent and prominent factors that trigger depression
and is often viewed as a predictor of a depressive disorder.
In one study self-reported sleep disturbance was a major
prodromal symptom 5 weeks prior to the recurrence of a
depressive episode (Perlis et al., 1997). Depressed
patients often complain of difficulties in falling asleep,
frequent nocturnal awakenings and early morning wakefulness. Further, more than 90% of depressed patients
suffer from impairment of sleep quality (Mendelson et al.,
1987).
Sleep disturbances in depressed patients have been
analyzed by polysomnography (PSG) (Fig. 1). A reduction in slow wave sleep, shortening of REM onset latency
(REMOL), increased REM sleep, and sleep continuity
disturbances were among the symptoms found in an
assessment of untreated depressed patients (Kupfer et al.,
1981). Indeed, REM sleep abnormalities are considered
specific for MDD although there are some controversies on this issue. In a retrospective study of 67 male
depressive patients and 67 carefully age-matched male
healthy control subjects Hubain et al. (2006) found that
the influence of age, severity, adaptation and gender were
strongly associated with depressive symptoms. (Hubain
et al., 2006). In contrast to most studies in this area, REM
sleep was found to be reduced. Further, aging was found
to influence most sleep variables, but not the order of
their association with depression. One of the main
markers of depression was the absence of sleep, a finding
204
V. Srinivasan et al. / Psychiatry Research 165 (2009) 201–214
that was interpreted to support the authors' conclusion
that a possible linkage between hyperarousal and stress
underlies its physiopathology (Hubain et al., 2006).
It is interesting to note that although unipolar and
bipolar types of depression can be clearly distinguished,
no significant differences between the two groups of
patients are observed in terms of nocturnal sleep patterns
(Duncan et al., 1979; Berger et al., 1982; Feinberg et al.,
1982; Lauer et al., 1992). Further, the sleep abnormalities
exhibited by manic patients are similar to those found in
unipolar and bipolar depressed individuals (Hudson et
al., 1992; Riemann et al., 2001). However, patients with
seasonal affective disorder (SAD) do not show the sleep
patterns seen in MDD (Anderson et al., 1994).
3. Sleep changes as markers for depression
Both epidemiological and electroencephalographic
studies implicate sleep disturbance in the pathogenesis of
depression (Lustberg and Reynolds, 2000). PSG studies
in depressed patients show a reduction in the absolute
number of delta waves during the first NREM sleep
period and a general decrease in delta activity throughout
the night (Fig. 1). Additionally, an alteration in the
temporal distribution of REM sleep with impairment of
the timing of the REM/NREM sleep cycle was documented (Buysse et al., 1997). It has been suggested that
patients with decreased REMOL prior to treatment are
prone of developing subsequent episodes of depression
and experiencing rapid relapses after remission (Rush
et al., 1989). The presence of sleep abnormalities in the
first degree relatives of depressed patients (even those
who never experienced the illness) suggests that these
sleep changes can be viewed as “markers” of depression
(Giles et al., 1990; Lustberg and Reynolds, 2000). The
decrease in slow wave activity during the first NREM
period and the increase of REM sleep occur more frequently in early depression although the significance of
this is not clear (Kupfer and Ehlers, 1989).
Functional neuroimaging studies using positron
emission tomography have indicated that MDD patients
have higher rates of brain glucose metabolism during the
first NREM sleep period as compared to non-depressed
controls, a change associated with decreased slow wave
activity (Gillin et al., 1996). Despite this associational
evidence, whether sleep disturbance has a causal role on
depression is still not completely resolved. However, the
clinical management of depression should entail an
awareness of the reciprocal relationship between insomnia and the depressive episodes (Lustberg and Reynolds,
2000). It has been suggested that the existence of
abnormalities in the timing of REM/NREM sleep cycle
in patients with depression is due to disturbances in the
organization of pathways active in regulation of the
sleep/wake cycle (Armitage, 2007).
4. Physiology of sleep regulatory mechanisms: role
of the melatonergic system
Two different processes participate in sleep regulation, namely, a homeostatic mechanism depending on
sleep debt and the circadian system that regulates sleep
induction and wakefulness (Borbely, 1982). NREM
sleep and, in particular, slow wave sleep, are controlled
by the homeostatic processes. In healthy young
individuals, sleep progresses through four non-REM
stages (stage 1 through stage 4), which take nearly 70 to
90 min (Fig. 1). Stage 1 sleep represents the transition
from drowsy wakefulness to deep sleep stages and
accounts for less than 5% of the total sleep at night.
Stage 2 sleep is characterized by the appearance of Kcomplexes and sleep spindles. Stage 3 and stage 4 are
deep stages of sleep (i.e. slow wave sleep) and display
desynchronized delta waves. Thereafter, the individual
enters into a REM sleep episode followed by reentry
into NREM. The elapsed time from sleep onset to the
beginning of the first REM period is called REMOL.
Periods of NREM sleep constitute nearly 80% of the
total sleep time while REM sleep accounts for 20% of the
sleep time. REM sleep grows longer with each successive ultradian cycle. During each night, individuals
experience approximately five cycles of NREM sleep
and REM sleep that last 70 to 90 min each. This entire
sequence of sleep stages throughout the night constitutes
the “sleep architecture” of an individual (Fuller et al.,
2006).
As mentioned above, physiological regulation of
sleep involves a homeostatic process (referred to as “S”,
for sleep) that depends upon sleep and wakefulness
period and a circadian process (“C”) that is independent
of sleep and waking behaviors (Borbely, 1982; Daan
et al., 1984). The S component controls NREM sleep
and the C component controls REM sleep and the ratio
of NREM/REM sleep.
The SCN interacts with both sleep regulatory mechanisms, S and C. Indeed, it has been suggested that a
functional disruption of the master clock plays a role in
disorders of sleep and wakefulness (Zee and Manthena,
2007). Isolation of the SCN from other regions of the
brain abolished circadian electrical activity in these
brain structures without affecting the circadian electrical
activity of SCN neurons (Inouye and Kawamura, 1979).
Melatonin is a major neurohormone influencing the
activity of SCN neurons. The effect of melatonin is
V. Srinivasan et al. / Psychiatry Research 165 (2009) 201–214
exerted via two distinct melatonin receptors, MT1 and
MT2 (Reppert et al., 1996; Dubocovich and Markowska,
2005). Melatonin inhibits (via MT1 receptors) as well as
phase-shifts (via MT2 receptors) the electrical activity of
SCN neurons (Mason and Brooks, 1988). In transgenic
mice lacking MT1 receptors, melatonin does not elicit
acute inhibitory responses but can still shift the phase of
circadian rhythmicity in SCN firing rate (Liu et al.,
1997). Therefore, MT2 receptors in the SCN are considered responsible for the phase-shifting and entrainment effects of melatonin. The firing rate of the SCN
decreases in the transition from NREM to REM sleep, as
shown by the simultaneous recording of electroencephalographic activity and SCN electrical activity in male
Wistar rats (Deboer et al., 2003). These observations
however require further confirmation in primates, since
the relative amount of REM sleep in rodents is quite
limited.
The role of the SCN in the regulation of sleep was
first studied in squirrel monkeys. In this primate species
SCN lesions, on the one hand, resulted in the loss of
consolidated sleep/wake periods and, on the other hand,
caused a prolonged sleep compared to animals with an
intact SCN (Edgar et al., 1993). The evidence supported
the conclusion that the circadian signal arising from the
SCN promotes wakefulness during the day and facilitates consolidation of sleep during the subjective night.
Indeed, the mechanisms by which the SCN regulates
sleep appear to be complex. The primary projections
from the SCN involve hypothalamic and extrahypothalamic structures (e.g., the basal forebrain or midline
thalamic nuclei) that are involved in the regulation of
sleep/wake cycle, autonomic regulation, psychomotor
performance and melatonin secretion (Abrahamson
et al., 2001; Aston-Jones, 2005; Saper et al., 2005).
The main purpose of the SCN output system is to
integrate environmental cues with the circadian system,
thus conferring maximum flexibility to the response
(Saper et al., 2005). Hence, the neural pathways from
the SCN, which promote wakefulness are complemented by those involved in SCN promotion of sleep (Zee
and Manthena, 2007). The sleep-promoting action of the
SCN also depends upon melatonin whose circadian
secretion is regulated by the SCN. Signals from the SCN
have been shown to influence physiology and behavior
including melatonin synthesis, temperature and sleep
(Bunney and Bunney, 2000).
5. Regulation of melatonin secretion by the SCN
Melatonin secretion from the pineal gland is greater
at night than during the day in all animal species, irres-
205
pective of whether they are diurnal, nocturnal or crepuscular (Cardinali and Pevet, 1998; Reiter, 2003;
Claustrat et al., 2005). The circadian pattern of
melatonin synthesis and secretion is abolished by SCN
lesions (Klein and Moore, 1979). The circadian activity
of the SCN is synchronized to the environmental light/
dark cycle by light perceived in the retina. The signal
from the retina is mainly transmitted to the SCN through
a monosynaptic retinohypothalamic tract that originates
from particular light-perceptive, melanopsin-containing
retinal ganglion cells (Berson et al., 2002), plus a minor
contribution given by mid-wavelength cones (Panda,
2007). Projections from the SCN pass through the paraventricular nucleus, medial forebrain bundle and
reticular formation to reach the intermediolateral horn
cells of the spinal cord. Fibers from these cells synapse
with neurons of the sympathetic superior cervical
ganglia, the source of the postganglionic sympathetic
innervation of the pineal gland (Klein et al., 1971). NE
released from the sympathetic nerve endings interacts
with β-adrenoceptors in the pinealocyes and activates
adenylate cyclase, thereby enhancing pineal melatonin
synthesis and secretion. During the light phase of the
daily photoperiod, when the SCN electrical activity is
high, NE release is low, while during scotophase, when
the SCN electrical activity is low, the increase in pineal
NE release stimulates melatonin synthesis and secretion
(Gerdin et al., 2004).
6. Melatonin's role in the regulation of sleep
The fact that the nocturnal increase of melatonin
secretion occurs approximately 2 h in advance to the
individual's habitual bedtime (Tzischinsky et al., 1993;
Shochat et al., 1997) and that this correlates well with
the onset of evening sleepiness have prompted many
investigators to suggest that melatonin is involved in the
physiological regulation of sleep (Zhdanova and Tucci,
2003). The period of wakefulness immediately prior to
the increase of sleep propensity (‘opening of sleep gate’)
is known as the ‘forbidden zone’ for sleep (Strogatz
et al., 1986; Lavie, 1986). During this time, the sleep
propensity is lowest and SCN neuronal activity is very
high (Buysse et al., 2004; Long et al., 2005). The
transition from wakefulness/arousal to high sleep propensity coincides with the nocturnal rise of melatonin
secretion (Dijk and Cajochen, 1997). Melatonin promotes sleep by inhibiting the firing of SCN neurons
through activation of GABAergic mechanisms in the
SCN (Niles, 1991; Golombek et al., 1996). From the
studies on the effects of melatonin administration on
sleep, it has been concluded that melatonin exerts both
206
V. Srinivasan et al. / Psychiatry Research 165 (2009) 201–214
direct hypnotic effects and circadian rhythm regulating
effects on sleep (Rajaratnam et al., 2004).
As discussed above, PSG studies of adults with major
depression have consistently shown that they suffer from
various sleep abnormalities such as prolonged sleep
onset latency, decreased slow wave sleep and increased
REM sleep and sleep fragmentation. Taken together, this
evidence suggests that melatonin, a major hormone involved in the regulation of sleep, merits consideration as
one of the triggering factors underlying the pathogenesis
of MDD and bipolar depressive disorder (Srinivasan
et al., 2006).
7. Melatonin in MDD
The nature of disruption of melatonin secretion in
MDD has been under intensive study ever since
Wetterberg and his co-workers proposed MDD as a
“low melatonin syndrome”, a concept that focuses on low
melatonin secretion as a biological marker for depression
(Wetterberg, 1979). A number of studies have reported
low nocturnal melatonin secretion in depressives
(Venkoba rao et al., 1983; Claustrat et al., 1984; Nair
et al., 1984; Brown et al., 1985; Beck-Friis et al., 1985;
Sack and Lewy, 1988). However, increases in melatonin
secretion in depressives has also been reported (Rubin et
al., 1992; Shafii et al., 1996; Sekula et al., 1997; Crasson
et al., 2004). The differences could be ascribed to
changes in depressive symptomatology or to the pattern
of melatonin secretion, inasmuch as there are studies
showing that daytime melatonin secretion in depressives
is increased (Crasson et al., 2004).
In a large scale study involving 382 postmenopausal women, the participants were asked to collect,
measure and record every fractional urine voiding
volume over two 24-h intervals in the course of the
week, approximately 3 days apart (an average of ten
specimens per 24 h) to measure urinary 6-sulfatoxymelatonin excretion (Tuunainen et al., 2002). 6Sulfatoxymelatonin is the major melatonin metabolite
in urine and is regarded as an index of melatonin
secretion rate (Bojkowski and Arendt, 1990). A
positive family history of depression was associated
with a longer duration of urinary 6-sulfatoxymelatonin
excretion (Tuunainen et al., 2002).
The association of depression and sleep disturbances
was evaluated in 459 postmenopausal women, in which
lower levels of illumination were found to be associated
with more complaints of sleep and depressive symptoms (Kripke et al., 2004). Bright light treatment
of women suffering from antepartum depression not
only advanced the rhythm of melatonin secretion, but
also mitigated depressive symptoms (Epperson et al.,
2004).
Studies of sleep in recurrent depressive and bipolar
disorders have been useful for constructing hypotheses
about the etiology and pathophysiology of the disease.
A marked reduction in sleep during the night immediately before switching from depression to mania was
noted in bipolar depressive patients (Bunney et al.,
1970; Sitaram et al., 1978; Wehr and Goodwin, 1979).
Measurements of melatonin levels have shown significantly lower levels in unipolar and bipolar depressive patients (Beck-Friis et al., 1985; Souetre et al.,
1989). Phase advances in melatonin secretion have also
been noted in bipolar depressive patients (Lewy et al.,
1979; Kennedy et al., 1989). The significance of the
association of sleep disturbances and melatonin levels
in bipolar depressive patients remains to be fully
elucidated.
Exogenous melatonin administration affects the
phase of the circadian oscillator regulating sleep/wakefulness (Arendt and Skene, 2005; Cardinali et al., 2006).
Kayumov et al. (2001) studied eight depressed patients
with an established diagnosis of delayed sleep phase
syndrome, and whose sleep onset time and wake time
were very much delayed. Melatonin treatment not only
improved the total sleep time but also decreased the
depressive symptoms (Kayumov et al., 2001), thus
showing a relationship between sleep disturbance and
the depressive symptomatology.
8. Antidepressants and sleep: role of the novel
melatonergic antidepressant agomelatine
As noted above, sleep disturbances are key features
of depressive symptomatology with more than 80% of
depressed patients complaining of sleep disturbances
(Reynolds and Kupler, 1988). Persistent insomnia is
also one of the main causes for increased risk of relapse
and recurrence of depression and also for increased risk
of suicide in adults (Wingard and Berkman, 1983; Ford
and Kamerow, 1989; Breslau et al., 1996). It is well
known that most depression severity rating scales focus
on insomnia or reduced total sleep time (Armitage,
2007). Disturbed sleep is one of the diagnostic criteria in
the DSM-IV for major depressive disorder. Decreases in
sleep efficiency, slow wave sleep and total sleep time,
and increases in awakenings and in sleep onset latency
time, have all been documented in patients with MDD
(Lam, 2006). Although some studies show persistence
of sleep architecture abnormalities even during remission phase (Rush et al., 1986) the improvement in the
clinical state (Kupfer et al., 1981) or relapse (Cairns
V. Srinivasan et al. / Psychiatry Research 165 (2009) 201–214
et al., 1980) are preceded by sleep changes. Hence the
administration of an appropriate antidepressant that
improves sleep efficiency as well as reducing depressive
symptomatology is very important for correcting the
underlying neurochemical or neurophysiological
abnormalities in MDD.
Classical antidepressants can influence sleep. However, the effects are diverse and vary among compounds.
Some of them that are in clinical use improve the sleep
of depressed patients after about 3 to 4 weeks of
treatment, but their greatest effects are on REM sleep,
with less consistent changes seen in NREM sleep (Lam,
2006). Compounds such as mianserin, nefazodone, and
trazodone (5-HT antagonists) may promote sleep and
improve its continuity (Argyropoulos and Wilson,
2005). However, the majority of available drugs generally produce unwanted negative effects on sleep
(Lam, 2006). Antidepressants such as TCAs or selective
serotonin reuptake inhibitors (SSRIs) suppress REM
sleep and increase REMOL (Sonntag et al., 1996;
Trivedi et al., 1999; Armitage et al., 2000).
Detailed analyses have revealed that drugs such as
SSRIs (which are the most widely prescribed antidepressants) have adverse effects on sleep, and the depression associated insomnia is often worsened by the
use of these drugs (Lam, 2006; Moltzen and BangAndersen, 2006). Hence, caution should be exercised in
choosing an antidepressant. An ideal agent should not
only mitigate symptoms of depression, but should also
decrease sleep onset difficulties, reduce wakefulness
after sleep onset, improve sleep quality and promote a
feeling of freshness on the day after (Kupfer, 2006).
Prolonged treatment with antidepressants such as
desipramine, clomipramine and fluoxetine has been
shown to affect the distribution of melatonin receptor
mRNAs in the brain. Most of the drugs increase the
amount of MT1 receptor mRNA in hippocampal regions
(Imbesi et al., 2006). The extent to which the
antidepressant response to a particular drug depends
upon the distribution of melatonin receptors in the brain
merits further detailed investigation (Hirsch-Rodriguez
et al., 2006).
Agomelatine is a naphthalenic compound chemically
designated as N-[2-(7-methoxynaphth-1-yl) ethyl]acetamide. It has been found to be effective as an
antidepressant not only in animal models of depression,
but also in patients with MDD. Agomelatine is a novel
antidepressant drug which acts simultaneously as a
melatonin MT1 and MT2 receptor agonist and as a 5HT2C antagonist (Yous et al., 1992; Millan et al., 2003).
This dual mechanism of action is unique and is the basis
of both its antidepressant efficacy and its capacity to
207
mitigate sleep–wakefulness rhythm disorders (Krauchi
et al., 1997). Agomelatine has been found to be effective
in several animal models of depression such as learned
helplessness (Bertaina-Anglade et al., 2002), chronic
mild stress (Papp et al., 2003), forced swimming
(Bourin et al., 2004), psychosocial stress in tree shrews
(Fuchs et al., 2006) and transgenic mice with decreased
glucocorticoid receptor (GR) expression (Barden et al.,
2005). The latter model is based on evidence indicating
that a malfunction of the GR system can be instrumental
in depression (Pepin et al., 1992). The antidepressant
activity of agomelatine was assessed in this transgenic
mouse model by using a forced swimming test (Barden
et al., 2005). In the same model, agomelatine was
investigated for anxiolytic properties in the elevated
plus maze. The effects of agomelatine were compared to
those of desipramine or melatonin. Drugs were injected
daily to mice i.p. at a 10 mg/kg dose for 21 to 42 days,
2 h before the onset of the dark period. Treatment with
agomelatine reversed the decreased mobility seen in the
transgenic mice in the forced swimming test, the effect
being comparable to that of melatonin or desipramine.
Both the number of open arm entries and the total time
spent in open arms of the elevated plus maze were
greatly increased in transgenic mice, and agomelatine
was effective in reversing the transgenic mouse
behavioral changes noted in the elevated plus maze
(Barden et al., 2005). In the same study, agomelatine
accelerated readjustment of circadian cycles of temperature and activity of transgenic mice following an
induced phase-shift, the effect of agomelatine being
more potent than that of melatonin (Barden et al., 2005).
This resynchronizing effect of agomelatine is of
considerable therapeutic value since an internal desynchronization of circadian rhythms (i.e., loss of synchronization between two or more rhythms so that they freerun with different periods within the same organism) is
presumably implicated in the pathophysiology of
depressive disorders (Wehr and Wirz-Justice, 1982;
Lader, in press). Therefore, the antidepressant action of
agomelatine could depend partially on its chronobiotic
properties.
In a multicenter, multinational placebo-controlled
study involving 711 patients from different European
countries, agomelatine at doses of 25 mg/day was found
to be very effective for improving depressive symptoms
(Loo et al., 2002). Its antagonism of 5-HT2C receptors
coupled with its action on melatonergic receptors in the
SCN, which can reset the disturbed circadian rhythms,
accounts for agomelatine's therapeutic efficacy in more
complex cases of depression (Rouillon, 2006). Because
of its rapid promotion of symptom relief, agomelatine is
208
V. Srinivasan et al. / Psychiatry Research 165 (2009) 201–214
an ideal choice for clinical cases of depression in which
sleep disturbance is a prominent feature (Pandi-Perumal
et al., 2006).
Effects on sleep require a distinction between chronobiological aspects and those related to sleep stages.
Concerning sleep architecture, different findings have
been reported. In an earlier study (Cajochen et al.,
1997), the acute administration of agomelatine for a
single night resulted in increases in REM sleep without
modifications of NREM sleep. In a more recent PSG
study of depressive patients, agomelatine treatment in
doses of 25 mg/day for 6 weeks improved both sleep
quality and continuity. It also increased the duration of
NREM sleep without modifying REM sleep (Salva
et al., 2007). These findings demonstrate that while
agomelatine's chronic and acute actions appear to be
different, its sleep-promoting benefits remain constant.
The chronobiotic potential of agomelatine, which is
not surprising in view of its melatonergic agonist effects,
also extends to the synchronization of various body
functions, a phenomenon which has been documented
in at least one study (Leproult et al., 2005). The available evidence thus suggests that agomelatine is involved
not only in sleep regulation but also promotes wakefulness (Dubocovich, 2006).
An ideal sleep-promoting compound should not
cause hangover effects nor impair daytime activity.
Agomelatine appears to approach this ideal inasmuch as
in two studies it only occasionally caused mild fatigue
(Pjrek et al., 2007), while improvements in daytime
alertness were observed in other cases (Kupfer, 2006).
The advantageous property of melatonergic agonists is
that they promote sleep, at reasonable doses, only in the
appropriate circadian phase, a characteristic also found
with another MT1/MT2 agonist, ramelteon, which is,
however, devoid of the 5-HT2C receptor antagonism
(Pandi-Perumal et al., 2007).
On the other hand, any antidepressant efficacy of
agomelatine requires a continual action during daytime.
On a solely chronobiological basis, agomelatine should
not behave differently from an agent like ramelteon,
which does not exhibit antidepressive properties (PandiPerumal et al., 2007). Therefore, agomelatine may
continually modulate the serotonergic system during the
day, without inducing sleepiness. Agomelatine's effects
appear to be mediated physiologically inasmuch as this
single compound, which also antagonizes 5-HT2C receptors at night, acts differently in different circadian
phases. These effects are in contrast to the mechanism of
more traditional antidepressants which elevate the
daytime mood of patients by activating the CNS. Consequently, if these drug effects are sustained into the
night their mode of action can impair sleep quality
(Ruhe et al., 2007). By contrast, agomelatine thus has a
dually phased mechanism of action. At night, its sleeppromoting melatonergic effects prevail over its potentially antihypnotic 5-HT2C antagonism, whereas during
the day, its antidepressant action via 5-HT2C inhibition
is uncoupled from melatonin's nocturnal actions. This
sequential mode could be regarded as a major advantage
of agomelatine over other antidepressants (Millan,
2006). An enhanced level of sleep quality elevates the
patient's mood in the morning and thus, while the antidepressant effect via 5-HT2C inhibition prevails during
the daytime hours, he experiences an improved quality
of life. Another, perhaps substantial, advantage of agomelatine is that it has concomitant, neurogenic action in
the hippocampus. This effect may underlie its antidepressant and anxiolytic properties (Banasr et al.,
2006) and can have value for long-term antidepressant
therapy.
The effectiveness of agomelatine's melatonergic and
selective antiserotonergic action has been confirmed in a
number of clinical trials. In a double-blind multicenter
trial involving a large population of MDD patients
(n = 165), the efficacy of agomelatine (25 mg/day) was
compared to that of venlafaxine (75 mg/day) (n = 167) in
terms of subjective sleep onset and sleep quality. At the
end of one week, agomelatine treatment significantly
improved subjective assessments of sleep onset and
quality when compared to venlafaxine. The improvement in sleep quality with preserved daytime alertness
as noted in this study was significant. A reduction in
depressive symptoms was shown by decreases in scores
on the Hamilton depression rating scale, which dropped
from 20.0 to 11. ± 9.9 following agomelatine treatment
(Guilleminault, 2005). Moreover, agomelatine improved sleep even before it elevated the mood thus
suggesting that the improvement of sleep in depressed
patients can be a prerequisite for improving their clinical
status (Lam, 2006).
The superior efficacy of agomelatine over other antidepressants has been consistently supported by many
investigations (Norman and Burrows, 2007). The drug
was also found to display excellent tolerability at a daily
dose of 25 mg and did not exhibit significant side effects
to the extent and severity observed with other antidepressants such as SSRIs (Zupancic and Guilleminault,
2006; Pjrek et al., 2007). In particular, it did not produce
sexual side effects (Montgomery, 2006), constipation,
body weight gain, orthostatic hypotension or memory
disorders (Hamon and Bourgoin, 2006). Moreover, agomelatine did not induce habituation nor addiction; for
instance, in preclinical tests it was not self-administered
V. Srinivasan et al. / Psychiatry Research 165 (2009) 201–214
by rhesus monkeys (Wiley et al., 1998) and accordingly,
did not cause discontinuation symptoms (Montgomery
et al., 2004).
Although there has been no evidence of mental side
effects associated with agomelatine an issue which
remains to be explored is its potential toxicity (e.g. hepatotoxicity) following long-term use. Inasmuch as
agomelatine is a naphthalenic compound, it should act
on the P450 system and therefore its effects should be
monitored closely.
9. Agomelatine in sleep disturbances of SAD
Seasonal affective disorder (SAD) or winter depression has been defined as a seasonal pattern of recurrent
major depressive episodes that occur during winter/fall
in the absence of seasonal psychosocial stressors, and
with a full remission of symptoms in the spring/summer
(American Psychiatric Association, 1994). A seasonal
pattern can also occur in MDD and bipolar depressive
disorder (Sohn and Lam, 2005; Lader, in press).
Epidemiological studies show that the incidence of
SAD in the general population is 15 to 25% (Axelsson et
al., 2002; Magnusson and Boivin, 2003). Patients with
SAD manifest atypical depressive symptoms such as
carbohydrate craving, hypersomnia, hyperphagia or
weight gain (Rosenthal et al., 1984).
Sleep disturbances are the hallmark of SAD and include hypersomnia, difficulty in waking up in the morning
and daytime sleepiness during the winter season. These
abnormal features disappear or are even reversed
throughout the summer remission with the opposite
symptoms of hyposomnia or insomnia (Rosenthal et al.,
1984). Hypersomnia and late awakening are regarded as
signs of both a phase delay and prolongation of melatonin
secretion (Putilov and Danilenko, 2005). The phase delay
of circadian rhythms relative to sleep that is documented
in patients with SAD has been given as possible explanation for hypersomnia (Avery et al., 1997).
It is well known that in human chronobiological
studies both core body temperature and melatonin secretion are used as “markers” for assessing circadian
phase position. The phase delay of the circadian pacemaker relative to timing of the habitual sleep–wake cycle
has been postulated to be a major contributing factor in
the pathophysiology of SAD (Koorengevel et al., 2002).
In some studies (Lewy et al., 1987, 1998; Sack et al.,
1990) the dim light melatonin onset (DLMO) test has
revealed that in patients with SAD the melatonin
secretory pattern is phase delayed. Other studies
(Checkley et al., 1993; Eastman et al., 1993; WirzJustice et al., 1996; Thompson et al., 1997) however
209
have not confirmed this finding. SAD patients have been
shown to exhibit longer periods of melatonin synthesis at
night during winter as compared to summer (Wehr et al.,
2001) thus suggesting that patients with SAD generate a
“biological signal” with change in season in a manner
similar to that of photoperiodic mammals.
Bright light treatment has been shown effective in
correcting not only the phase abnormality of SAD patients but also their depressive symptoms as well. In a 4week long study it was found that application of bright
light (2500 lx) for 2 h in the morning (0600–0800 h)
normalized circadian rhythmicity in core body temperature, cortisol and mood (Avery et al., 1997). Similarly,
application of bright light for 7 days in the morning
(0600–0800 h) improved scores in the Structured
Interview Guide for the Hamilton Depression Rating
Scale, SAD version (SIGH-SAD) in SAD patients (Rice
et al., 1995). A significant correlation between the
magnitude of phase advances of melatonin secretion
after morning light and the improvement in the depression scores was observed (Terman et al., 2001).
Bright light of high intensity (10 000 lx) was applied in
that study for about 30 min. Terman et al. (2001) suggested that the best treatment for winter depression was
to expose the patients to bright light 8.5 h after DLMO.
Following the identification of agomelatine as a
MT1/MT2 melatonergic agonist with antidepressant
properties, its efficacy was tested in 37 acutely depressed SAD patients (Pjrek et al., 2007). In an open
study with agomelatine (25 mg/day in the evening) over
14 weeks, treatment outcome was assessed by the
SIGH-SAD scale and Circscreen, a self-rating scale for
the assessment of sleep and circadian rhythm disorders
(Laredo et al., 2002). Agomelatine led to a progressive
and statistically significant decrease of SAD symptoms
from week 2 onward. Overall, treatment with agomelatine yielded a response rate of 75.7% and a remission
rate of 70.3%. Throughout the study only one adverse
event (mild fatigue) was related to the drug (Pjrek et al.,
2007). These results indicate that SAD can be
effectively and safely treated with agomelatine.
10. Conclusions
Epidemiological and electroencephalographic studies implicate serious sleep disturbances as one of the
major underlying causes in MDD and bipolar disorder.
Physiological sleep regulatory mechanisms include the
active role of the SCN and modulatory effects of melatonin on the electrical activity of the SCN. Disturbances in the rhythm and the amplitude of melatonin
secretion could account for symptomatic disturbances to
210
V. Srinivasan et al. / Psychiatry Research 165 (2009) 201–214
both sleep and mood. Antidepressants that are in use
today have both beneficial and adverse effects on sleep.
The recently introduced melatonergic antidepressant
agomelatine with its melatonin agonist property and 5HT2C antagonist property has shown effectiveness for
reducing symptoms. Additionally it has a demonstrated
superiority over other antidepressants for improving
sleep quality. It also has been found effective in
alleviating sleep problems of patients with SAD.
Analysis of factors involved in the disturbances of
sleep and melatonin secretion suggest that disturbances
of both these parameters may be contributing causal
factors in the pathophysiology of depression.
Acknowledgements
The authors sincerely acknowledge the enthusiastic
and constructive comments of several anonymous reviewers on the earlier version of this manuscript. Their
comments helped us greatly to improve the final version
of this manuscript. We also would like to thank Ms.
Puan Rosnida Said, Department of Physiology, School
of Medical Sciences, University Sains Malaysia,
Malaysia, for her secretarial assistance.
References
Abrahamson, E.E., Leak, R.K., Moore, R.Y., 2001. The suprachiasmatic nucleus projects to posterior hypothalamic arousal systems.
Neuroreport 12, 435–440.
American Psychiatric Association, 1994. Diagnostic and Statistical
Manual of Mental Disorders. 4th Ed (DSM-IV). American Psychiatric Press, Washington, DC.
Anderson, J.L., Rosen, L.N., Mendelson, W.B., Jacobsen, F.M., Skwerer,
R.G., Joseph-Vanderpool, J.R., Duncan, C.C., Wehr, T.A., Rosenthal,
N.E., 1994. Sleep in fall/winter seasonal affective disorder: effects of
light and changing seasons. Journal of Psychosomatic Research 38,
323–337.
Arendt, J., Skene, D.J., 2005. Melatonin as a chronobiotic. Sleep
Medicine Reviews 9, 25–39.
Argyropoulos, S.V., Wilson, S.J., 2005. Sleep disturbances in depression and the effects of antidepressants. International Review of
Psychiatry 17, 237–245.
Armitage, R., 2007. Sleep and circadian rhythms in mood disorders.
Acta Psychiatrica Scandinavica 104–115 Suppl.
Armitage, R., Hoffmann, R.F., 2001. Sleep EEG, depression and
gender. Sleep Medicine Reviews 5, 237–246.
Armitage, R., Hoffmann, R., Fitch, T., Trivedi, M., Rush, A.J., 2000.
Temporal characteristics of delta activity during NREM sleep in
depressed outpatients and healthy adults: group and sex effects.
Sleep 23, 607–617.
Aston-Jones, G., 2005. Brain structures and receptors involved in
alertness. Sleep Medicine 6 (Suppl 1), S3–S7.
Avery, D.H., Dahl, K., Savage, M.V., Brengelmann, G.L., Larsen, L.H.,
Kenny, M.A., Eder, D.N., Vitiello, M.V., Prinz, P.N., 1997.
Circadian temperature and cortisol rhythms during a constant
routine are phase-delayed in hypersomnic winter depression. Biological Psychiatry 41, 1109–1123.
Axelsson, J., Karadottir, R., Karlsson, M.M., 2002. Differences in
prevalence of seasonal affective disorder that are not explained by
either genetic or latitude differences. International Journal of Circumpolar Health 61, 17–20.
Banasr, M., Soumier, A., Hery, M., Mocaer, E., Daszuta, A., 2006.
Agomelatine, a new antidepressant, induces regional changes in
hippocampal neurogenesis. Biological Psychiatry 59, 1087–1096.
Barden, N., Shink, E., Labbe, M., Vacher, R., Rochford, J., Mocaer, E.,
2005. Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Progress in Neuropsychopharmacology and
Biological Psychiatry 29, 908–916.
Beck-Friis, J., Kjellman, B.F., Aperia, B., Unden, F., von Rosen, D.,
Ljunggren, J.G., Wetterberg, L., 1985. Serum melatonin in relation
to clinical variables in patients with major depressive disorder and
a hypothesis of a low melatonin syndrome. Acta Psychiatrica
Scandinavica 71, 319–330.
Berger, M., Doerr, P., Lund, R., Bronisch, T., von Zerssen, D., 1982.
Neuroendocrinological and neurophysiological studies in major
depressive disorders: are there biological markers for the endogenous subtype? Biological Psychiatry 17, 1217–1242.
Berson, D.M., Dunn, F.A., Takao, M., 2002. Phototransduction by retinal
ganglion cells that set the circadian clock. Science 295, 1070–1073.
Bertaina-Anglade, V., Mocaer, E., Drieu La Rochelle, C., 2002.
Antidepressant-like action of S20098 (agomelatine) in the learned
helplessness test. International Journal of Neuropsychopharmacology 5 (suppl 1), S65.
Berton, O., Nestler, E.J., 2006. New approaches to antidepressant drug
discovery: beyond monoamines. Nature Reviews Neuroscience 7,
137–151.
Bojkowski, C.J., Arendt, J., 1990. Factors influencing urinary 6-sulphatoxymelatonin, a major melatonin metabolite, in normal human
subjects. Clinical Endocrinology (Oxford) 33, 435–444.
Borbely, A.A., 1982. A two process model of sleep regulation. Human
Neurobiology 1, 195–204.
Bourin, M., Mocaer, E., Porsolt, R., 2004. Antidepressant-like activity
of S 20098 (agomelatine) in the forced swimming test in rodents:
involvement of melatonin and serotonin receptors. Journal of
Psychiatry and Neuroscience 29, 126–133.
Breslau, N., Roth, T., Rosenthal, L., Andreski, P., 1996. Sleep
disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biological Psychiatry 39,
411–418.
Brown, R., Kocsis, J.H., Caroff, S., Amsterdam, J., Winokur, A.,
Stokes, P.E., Frazer, A., 1985. Differences in nocturnal melatonin
secretion between melancholic depressed patients and control
subjects. American Journal of Psychiatry 142, 811–816.
Bunney, W.E., Bunney, B.G., 2000. Molecular clock genes in man and
lower animals: possible implications for circadian abnormalities in
depression. Neuropsychopharmacology 22, 335–345.
Bunney Jr., W.E., Murphy, D.L., Goodwin, F.K., Borge, G.F., 1970.
The switch process from depression to mania: relationship to drugs
which alter brain amines. Lancet 1, 1022–1027.
Buysse, D.J., Frank, E., Lowe, K.K., Cherry, C.R., Kupfer, D.J., 1997.
Electroencephalographic sleep correlates of episode and vulnerability to recurrence in depression. Biological Psychiatry 41,
406–418.
Buysse, D.J., Nofzinger, E.A., Germain, A., Meltzer, C.C., Wood, A.,
Ombao, H., Kupfer, D.J., Moore, R.Y., 2004. Regional brain
glucose metabolism during morning and evening wakefulness in
humans: preliminary findings. Sleep 27, 1245–1254.
V. Srinivasan et al. / Psychiatry Research 165 (2009) 201–214
Cairns, J., Waldron, J., MacLean, A.W., Knowles, J.B., 1980. Sleep
and depression: a case study of EEG sleep prior to relapse. Canadian Journal of Psychiatry 25, 259–263.
Cajochen, C., Krauchi, K., Mori, D., Graw, P., Wirz-Justice, A., 1997.
Melatonin and S-20098 increase REM sleep and wake-up propensity without modifying NREM sleep homeostasis. American
Journal of Physiology 272, R1189–R1196.
Cardinali, D.P., Pevet, P., 1998. Basic aspects of melatonin action.
Sleep Medicine Reviews 2, 175–190.
Cardinali, D.P., Furio, A.M., Reyes, M.P., Brusco, L.I., 2006. The use
of chronobiotics in the resynchronization of the sleep/wake cycle.
Cancer Causes & Control 17 (4), 601–609.
Checkley, S.A., Murphy, D.G., Abbas, M., Marks, M., Winton, F.,
Palazidou, E., Murphy, D.M., Franey, C., Arendt, J., 1993. Melatonin rhythms in seasonal affective disorder. British Journal of
Psychiatry 163, 332–337.
Claustrat, B., Chazot, G., Brun, J., Jordan, D., Sassolas, G., 1984.
A chronobiological study of melatonin and cortisol secretion in
depressed subjects: plasma melatonin, a biochemical marker in
major depression. Biological Psychiatry 19, 1215–1228.
Claustrat, B., Brun, J., Chazot, G., 2005. The basic physiology and
pathophysiology of melatonin. Sleep Medicine Reviews 9,
11–24.
Crasson, M., Kjiri, S., Colin, A., Kjiri, K., L'hermite-Baleriaux, M.,
Ansseau, M., Legros, J.J., 2004. Serum melatonin and urinary 6sulfatoxymelatonin in major depression. Psychoneuroendocrinology 29, 1–12.
Daan, S., Beersma, D.G., Borbely, A.A., 1984. Timing of human
sleep: recovery process gated by a circadian pacemaker. American
Journal of Physiology 246, R161–R183.
Deboer, T., Vansteensel, M.J., Detari, L., Meijer, J.H., 2003. Sleep
states alter activity of suprachiasmatic nucleus neurons. Nature
Neuroscience 6, 1086–1090.
Dijk, D.J., Cajochen, C., 1997. Melatonin and the circadian regulation
of sleep initiation, consolidation, structure, and the sleep EEG.
Journal of Biological Rhythms 12, 627–635.
Drevets, W.C., 2001. Neuroimaging and neuropathological studies of
depression: implications for the cognitive–emotional features of
mood disorders. Current Opinions in Neurobiology 11, 240–249.
Dubocovich, M.L., 2006. Agomelatine targets a range of major depressive disorder symptoms. Current Opinion in Investigational
Drugs 7, 670–680.
Dubocovich, M.L., Markowska, M., 2005. Functional MT1 and MT2
melatonin receptors in mammals. Endocrine 27, 101–110.
Duncan Jr., W.C., Pettigrew, K.D., Gillin, J.C., 1979. REM architecture changes in bipolar and unipolar depression. American
Journal of Psychiatry 136, 1424–1427.
Eastman, C.I., Gallo, L.C., Lahmeyer, H.W., Fogg, L.F., 1993. The
circadian rhythm of temperature during light treatment for winter
depression. Biological Psychiatry 34, 210–220.
Edgar, D.M., Dement, W.C., Fuller, C.A., 1993. Effect of SCN lesions
on sleep in squirrel monkeys: evidence for opponent processes in
sleep–wake regulation. Journal of Neuroscience 13, 1065–1079.
Epperson, C.N., Terman, M., Terman, J.S., Hanusa, B.H., Oren, D.A.,
Peindl, K.S., Wisner, K.L., 2004. Randomized clinical trial of
bright light therapy for antepartum depression: preliminary findings. Journal of Clinical Psychiatry 65, 421–425.
Feinberg, M., Gillin, J.C., Carroll, B.J., Greden, J.F., Zis, A.P., 1982.
EEG studies of sleep in the diagnosis of depression. Biological
Psychiatry 17, 305–316.
Ford, D.E., Kamerow, D.B., 1989. Epidemiologic study of sleep
disturbances and psychiatric disorders. An opportunity for pre-
211
vention? Journal of the American Medical Association 262,
1479–1484.
Fuchs, E., Simon, M., Schmelting, B., 2006. Pharmacology of a new
antidepressant: benefit of the implication of the melatonergic
system. International Clinical Psychopharmacology 21 Suppl 1,
S17–S20.
Fuller, P.M., Gooley, J.J., Saper, C.B., 2006. Neurobiology of the
sleep–wake cycle: sleep architecture, circadian regulation, and
regulatory feedback. Journal of Biological Rhythms 21, 482–493.
Gerdin, M.J., Masana, M.I., Rivera-Bermudez, M.A., Hudson, R.L.,
Earnest, D.J., Gillette, M.U., Dubocovich, M.L., 2004. Melatonin
desensitizes endogenous MT2 melatonin receptors in the rat
suprachiasmatic nucleus: relevance for defining the periods of
sensitivity of the mammalian circadian clock to melatonin. FASEB
Journal 18, 1646–1656.
Giles, D.E., Etzel, B.A., Biggs, M.M., 1990. Risk factors in unipolar
depression: II. Relation between proband REM latency and
cognitions of relatives. Psychiatry Research 33, 39–49.
Gillin, J.C., Buchsbaum, M.S., Valladares-Neto, D.C., Hong, C.C.,
Hazlett, E., Langer, S.Z., Wu, J., 1996. Effects of zolpidem on local
cerebral glucose metabolism during non-REM sleep in normal
volunteers: a positron emission tomography study. Neuropsychopharmacology 15, 302–313.
Golombek, D.A., Pevet, P., Cardinali, D.P., 1996. Melatonin effect on
behavior: possible mediation by the central GABAergic system.
Neuroscience Biobehavioral Reviews 20, 403–412.
Guilleminault, C., 2005. Efficacy of agomelatine versus venlafaxine
on subjective sleep of patients with major depressive disorder.
European Neuropsychopharmacology 15 Suppl 3, S419.
Hamon, M., Bourgoin, S., 2006. Pharmacological profile of antidepressants: a likely basis for their efficacy and side effects?
European Neuropsychopharmacology 16 (Suppl 5), S625–S632.
Hirsch-Rodriguez, E., Imbesi, M., Manev, R., Uz, T., Manev, H., 2006.
The pattern of melatonin receptor expression in the brain may
influence antidepressant treatment. Medical Hypotheses 69,
120–124.
Hubain, P., Le Bon, O., Vandenhende, F., Van Wijnendaele, R.,
Linkowski, P., 2006. Major depression in males: effects of age,
severity and adaptation on sleep variables. Psychiatry Research
145, 169–177.
Hudson, J.I., Lipinski, J.F., Keck Jr., P.E., Aizley, H.G., Lukas, S.E.,
Rothschild, A.J., Waternaux, C.M., Kupfer, D.J., 1992. Polysomnographic characteristics of young manic patients. Comparison with unipolar depressed patients and normal control subjects.
Archives of General Psychiatry 49, 378–383.
Imbesi, M., Uz, T., Yildiz, S., Arslan, A.D., Manev, H., 2006. Drug
and region-specific effects of protracted antidepressant and cocaine
treatment on the content of melatonin MT1 and MT2 receptor
mRNA in the mouse brain. International Journal of Neuroprotection and Neurogenetics 2, 185–189.
Inouye, S.T., Kawamura, H., 1979. Persistence of circadian rhythmicity in a mammalian hypothalamic “island” containing the suprachiasmatic nucleus. Proceedings of the National Academy of
Sciences U. S. A. 76, 5962–5966.
Kayumov, L., Brown, G., Jindal, R., Buttoo, K., Shapiro, C.M., 2001.
A randomized, double-blind, placebo-controlled crossover study
of the effect of exogenous melatonin on delayed sleep phase syndrome. Psychosomatic Medicine 63, 40–48.
Kennedy, S.H., Tighe, S., McVey, G., Brown, G.M., 1989. Melatonin
and cortisol “switches” during mania, depression, and euthymia in
a drug-free bipolar patient. Journal of Nervous and Mental Disorders 177, 300–303.
212
V. Srinivasan et al. / Psychiatry Research 165 (2009) 201–214
Klein, D.C., Moore, R.Y., 1979. Pineal N-acetyltransferase and
hydroxyindole-O-methyltransferase: control by the retinohypothalamic tract and the suprachiasmatic nucleus. Brain Research 174,
245–262.
Klein, D.C., Weller, J.L., Moore, R.Y., 1971. Melatonin metabolism:
neural regulation of pineal serotonin: acetyl coenzyme A Nacetyltransferase activity. Proceedings of the National Academy of
Sciences U. S. A. 68, 3107–3110.
Klerman, E.B., Boulos, Z., Edgar, D.M., Mistlberger, R.E., MooreEde, M.C., 1999. Circadian and homeostatic influences on sleep
in the squirrel monkey: sleep after sleep deprivation. Sleep 22,
45–59.
Koorengevel, K.M., Beersma, D.G., den Boer, J.A., van den
Hoofdakker, R.H., 2002. A forced desynchrony study of circadian
pacemaker characteristics in seasonal affective disorder. Journal of
Biological Rhythms 17, 463–475.
Krauchi, K., Cajochen, C., Mori, D., Graw, P., Wirz-Justice, A., 1997.
Early evening melatonin and S-20098 advance circadian phase and
nocturnal regulation of core body temperature. American Journal
of Physiology 272, R1178–R1188.
Kripke, D.F., Jean-Louis, G., Elliott, J.A., Klauber, M.R., Rex, K.M.,
Tuunainen, A., Langer, R.D., 2004. Ethnicity, sleep, mood, and
illumination in postmenopausal women. BMC Psychiatry 4, 8.
Kupfer, D.J., 2006. Depression and associated sleep disturbances:
patient benefits with agomelatine. European Neuropsychopharmacology 16 (Suppl 5), S639–S643.
Kupfer, D.J., Ehlers, C.L., 1989. Two roads to rapid eye movement
latency. Archives of General Psychiatry 46, 945–948.
Kupfer, D.J., Spiker, D.G., Coble, P.A., Neil, J.F., Ulrich, R., Shaw, D.H.,
1981. Sleep and treatment prediction in endogenous depression.
American Journal of Psychiatry 138, 429–434.
Lader, M., in press. Limitations of current medical treatments for
depression: Disturbed circadian rhythms as a possible therapeutic
target. European Neuropsychopharmacology in press.
Lam, R.W., 2006. Sleep disturbances and depression: a challenge for
antidepressants. International Clinical Psychopharmacology 21
(Suppl 1), S25–S29.
Laredo, J., Quera-Salva, M.A., Flissard, B., de Bodinat, C., 2002.
Screening of sleep and circadian rhythms in major depression.
Journal of Sleep Research 11 (suppl. 1), 132–133.
Lauer, C.J., Wiegand, M., Krieg, J.C., 1992. All-night electroencephalographic sleep and cranial computed tomography in depression.
A study of unipolar and bipolar patients. European Archives of
Psychiatry and Clinical Neuroscience 242, 59–68.
Lavie, P., 1986. Ultrashort sleep–waking schedule. III. ‘Gates’ and
‘forbidden zones’ for sleep. Electroencephalography and Clinical
Neurophysiology 63, 414–425.
Leproult, R., Van Onderbergen, A., L'hermite-Baleriaux, M., Van
Cauter, E., Copinschi, G., 2005. Phase-shifts of 24-h rhythms of
hormonal release and body temperature following early evening
administration of the melatonin agonist agomelatine in healthy
older men. Clinical Endocrinology (Oxford) 63, 298–304.
Lewy, A.J., Wehr, T., Gold, P.W., Goodwin, F.K., 1979. Plasma
melatonin in manic depressive illness. In: Usdin, E., Kopin, I.J.,
Barchas, J.D. (Eds.), Catecholamines: Basic and Clinical Frontiers,
vol II. Pergamon Press, Oxford, pp. 1173–1175.
Lewy, A.J., Sack, R.L., Singer, C.M., White, D.M., 1987. The phase
shift hypothesis for bright light's therapeutic mechanism of action:
theoretical considerations and experimental evidence. Psychopharmacological Bulletin 23, 349–353.
Lewy, A.J., Bauer, V.K., Cutler, N.L., Sack, R.L., Ahmed, S., Thomas,
K.H., Blood, M.L., Jackson, J.M., 1998. Morning vs evening light
treatment of patients with winter depression. Archives of General
Psychiatry 55, 890–896.
Liu, C., Weaver, D.R., Jin, X., Shearman, L.P., Pieschl, R.L., Gribkoff,
V.K., Reppert, S.M., 1997. Molecular dissection of two distinct
actions of melatonin on the suprachiasmatic circadian clock.
Neuron 19, 91–102.
Long, M.A., Jutras, M.J., Connors, B.W., Burwell, R.D., 2005.
Electrical synapses coordinate activity in the suprachiasmatic nucleus. Nature Neuroscience 8, 61–66.
Loo, H., Hale, A., D'haenen, H., 2002. Determination of the dose of
agomelatine, a melatoninergic agonist and selective 5-HT(2C)
antagonist, in the treatment of major depressive disorder: a placebocontrolled dose range study. International Clinical Psychopharmacology 17, 239–247.
Lustberg, L., Reynolds, C.F., 2000. Depression and insomnia:
questions of cause and effect. Sleep Medicine Reviews 4,
253–262.
Magnusson, A., Boivin, D., 2003. Seasonal affective disorder: an
overview. Chronobiology International 20, 189–207.
Mason, R., Brooks, A., 1988. The electrophysiological effects of
melatonin and a putative melatonin antagonist (N-acetyltryptamine) on rat suprachiasmatic neurones in vitro. Neuroscience
Letters 95, 296–301.
Mayberg, H.S., 2003. Positron emission tomography imaging in depression: a neural systems perspective. Neuroimaging Clinics of
North America 13, 805–815.
McArthur, A.J., Hunt, A.E., Gillette, M.U., 1997. Melatonin action
and signal transduction in the rat suprachiasmatic circadian clock:
activation of protein kinase C at dusk and dawn. Endocrinology
138, 627–634.
Mendelson, W.B., Sack, D.A., James, S.P., Martin, J.V., Wagner, R.,
Garnett, D., Milton, J., Wehr, T.A., 1987. Frequency analysis of the
sleep EEG in depression. Psychiatry Research 21, 89–94.
Millan, M.J., 2006. Multi-target strategies for the improved treatment
of depressive states: conceptual foundations and neuronal
substrates, drug discovery and therapeutic application. Pharmacology and Therapeutics 110, 135–370.
Millan, M.J., Gobert, A., Lejeune, F., Dekeyne, A., Newman-Tancredi,
A., Pasteau, V., Rivet, J.M., Cussac, D., 2003. The novel melatonin
agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of
frontocortical dopaminergic and adrenergic pathways. Journal of
Pharmacology and Experimental Therapeutics 306, 954–964.
Moltzen, E.K., Bang-Andersen, B., 2006. Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a
century—a medicinal chemistry survey. Current Topics in Medicinal Chemistry 6, 1801–1823.
Montgomery, S.A., 2006. Major depressive disorders: clinical efficacy
and tolerability of agomelatine, a new melatonergic agonist. European Neuropsychopharmacology 16 (Suppl 5), S633–S638.
Montgomery, S.A., Kennedy, S.H., Burrows, G.D., Lejoyeux, M.,
Hindmarch, I., 2004. Absence of discontinuation symptoms with
agomelatine and occurrence of discontinuation symptoms with
paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. International Clinical Psychopharmacology 19,
271–280.
Nair, N.P., Hariharasubramanian, N., Pilapil, C., 1984. Circadian
rhythm of plasma melatonin in endogenous depression. Progress in
Neuropsychopharmacology and Biological Psychiatry 8, 715–718.
Nestler, E.J., Barrot, M., DiLeone, R.J., Eisch, A.J., Gold, S.J.,
Monteggia, L.M., 2002. Neurobiology of depression. Neuron 34,
13–25.
V. Srinivasan et al. / Psychiatry Research 165 (2009) 201–214
Niles, L., 1991. Melatonin interaction with the benzodiazepine–
GABA receptor complex in the CNS. Advances in Experimental
Medical Biology 294, 267–277.
Norman, T.R., Burrows, G.D., 2007. Emerging treatments for major
depression. Expert Reviews in Neurotherapeutics 7, 203–213.
Panda, S., 2007. Multiple photopigments entrain the Mammalian circadian oscillator. Neuron 53, 619–621.
Pandi-Perumal, S.R., Srinivasan, V., Cardinali, D.P., Monti, J.M.,
2006. Could agomelatine be the ideal antidepressant? Expert
Review Neurotherapeutics 6, 1595–1608.
Pandi-Perumal, S.R., Srinivasan, V., Poeggeler, B., Hardeland, R.,
Cardinali, D.P., 2007. Drug insight: the use of melatonergic agonists for the treatment of insomnia — focus on ramelteon. Nature
Clinical Practice Neurology 3 (4), 221–228.
Papp, M., Gruca, P., Boyer, P.A., Mocaer, E., 2003. Effect of agomelatine in the chronic mild stress model of depression in the rat.
Neuropsychopharmacology 28, 694–703.
Pepin, M.C., Pothier, F., Barden, N., 1992. Antidepressant drug action
in a transgenic mouse model of the endocrine changes seen in
depression. Molecular Pharmacology 42, 991–995.
Perlis, M.L., Giles, D.E., Buysse, D.J., Tu, X., Kupfer, D.J., 1997.
Self-reported sleep disturbance as a prodromal symptom in recurrent depression. Journal of Affective Disorders 42, 209–212.
Pjrek, E., Winkler, D., Konstantinidis, A., Willeit, M., Praschak-Rieder,
N., Kasper, S., 2007. Agomelatine in the treatment of seasonal
affective disorder. Psychopharmacology (Berlin) 190, 575–579.
Putilov, A.A., Danilenko, K.V., 2005. Antidepressant effects of light
therapy and “natural” treatments for winter depression. Biological
Rhythm Research 36, 423–437.
Rajaratnam, S.M., Middleton, B., Stone, B.M., Arendt, J., Dijk, D.J.,
2004. Melatonin advances the circadian timing of EEG sleep and
directly facilitates sleep without altering its duration in extended
sleep opportunities in humans. Journal of Physiology 561,
339–351.
Reiter, R.J., 2003. Melatonin: clinical relevance. Best Practice &
Research. Clinical Endocrinology & Metabolism 17, 273–285.
Reppert, S.M., Weaver, D.R., Godson, C., 1996. Melatonin receptors
step into the light: cloning and classification of subtypes. Trends in
Pharmacological Sciences 17, 100–102.
Reynolds, C.F., Kupler, D., 1988. Sleep in depression. In: Williams, R.Z.,
Karacan, I., Moore, C.A. (Eds.), Sleep disorders, diagnosis and
treatment. John Wiley, New York, pp. 147–164.
Rice, J., Mayor, J., Tucker, H.A., Bielski, R.J., 1995. Effect of light
therapy on salivary melatonin in seasonal affective disorder. Psychiatry Research 56, 221–228.
Riemann, D., Berger, M., Voderholzer, U., 2001. Sleep and depression—results from psychobiological studies: an overview. Biological Psychology 57, 67–103.
Rosenthal, N.E., Sack, D.A., Gillin, J.C., Lewy, A.J., Goodwin, F.K.,
Davenport, Y., Mueller, P.S., Newsome, D.A., Wehr, T.A., 1984.
Seasonal affective disorder. A description of the syndrome and
preliminary findings with light therapy. Archives of General Psychiatry 41, 72–80.
Rosenzweig-Lipson, S., Beyer, C.E., Hughes, Z.A., Khawaja, X.,
Rajarao, S.J., Malberg, J.E., Rahman, Z., Ring, R.H., Schechter,
L.E., 2007. Differentiating antidepressants of the future: efficacy
and safety. Pharmacology and Therapeutics 113, 134–153.
Rouillon, F., 2006. Efficacy and tolerance profile of agomelatine and
practical use in depressed patients. International Clinical Psychopharmacology 21 Suppl 1, S31–S35.
Rubin, R.T., Heist, E.K., McGeoy, S.S., Hanada, K., Lesser, I.M.,
1992. Neuroendocrine aspects of primary endogenous depression.
213
XI. Serum melatonin measures in patients and matched control
subjects. Archives of General Psychiatry 49, 558–567.
Ruhe, H.G., Mason, N.S., Schene, A.H., 2007. Mood is indirectly
related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Molecular
Psychiatry 12, 331–359.
Rush, A.J., Erman, M.K., Giles, D.E., Schlesser, M.A., Carpenter, G.,
Vasavada, N., Roffwarg, H.P., 1986. Polysomnographic findings in
recently drug-free and clinically remitted depressed patients. Archives of General Psychiatry 43, 878–884.
Rush, A.J., Giles, D.E., Jarrett, R.B., Feldman-Koffler, F., Debus, J.R.,
Weissenburger, J., Orsulak, P.J., Roffwarg, H.P., 1989. Reduced
REM latency predicts response to tricyclic medication in depressed
outpatients. Biological Psychiatry 26, 61–72.
Sack, R.L., Lewy, A.J., 1988. Melatonin and major affective disorders.
In: Miles, A., Philbrich, D., Thompson, C. (Eds.), Melatonin:
Clinical Perspectives. Oxford Medical Publications, New York,
pp. 205–227.
Sack, R.L., Lewy, A.J., White, D.M., Singer, C.M., Fireman, M.J.,
Vandiver, R., 1990. Morning vs evening light treatment for winter
depression. Evidence that the therapeutic effects of light are mediated by circadian phase shifts. Archives of General Psychiatry
47, 343–351.
Salva, M.A., Vanier, B., Laredo, J., Hartley, S., Chapotot, F., Moulin,
C., Lofaso, F., Guilleminault, C., 2007. Major depressive disorder,
sleep EEG and agomelatine: an open-label study. International
Journal of Neuropsychopharmacology 1–6.
Saper, C.B., Scammell, T.E., Lu, J., 2005. Hypothalamic regulation of
sleep and circadian rhythms. Nature 437, 1257–1263.
Sekula, L.K., Lucke, J.F., Heist, E.K., Czambel, R.K., Rubin, R.T.,
1997. Neuroendocrine aspects of primary endogenous depression.
XV: Mathematical modeling of nocturnal melatonin secretion in
major depressives and normal controls. Psychiatry Research 69,
143–153.
Shafii, M., MacMillan, D.R., Key, M.P., Derrick, A.M., Kaufman, N.,
Nahinsky, I.D., 1996. Nocturnal serum melatonin profile in major
depression in children and adolescents. Archives of General Psychiatry 53, 1009–1013.
Shochat, T., Luboshitzky, R., Lavie, P., 1997. Nocturnal melatonin
onset is phase locked to the primary sleep gate. American Journal
of Physiology 273, R364–R370.
Sitaram, N., Gillin, J.C., Bunney Jr., W.E., 1978. The switch process in
manic-depressive illness. Circadian variation in time of switch and
sleep and manic ratings before and after switch. Acta Psychiatrica
Scandinavica 58, 267–278.
Sohn, C.H., Lam, R.W., 2005. Update on the biology of seasonal
affective disorder. CNS Spectrums 10, 635–646.
Sonntag, A., Rothe, B., Guldner, J., Yassouridis, A., Holsboer, F.,
Steiger, A., 1996. Trimipramine and imipramine exert different
effects on the sleep EEG and on nocturnal hormone secretion
during treatment of major depression. Depression 4, 1–13.
Souetre, E., Salvati, E., Belugou, J.L., Pringuey, D., Candito, M., Krebs,
B., Ardisson, J.L., Darcourt, G., 1989. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main
chronobiological abnormality. Psychiatry Research 28, 263–278.
Srinivasan, V., Smits, M., Spence, W., Lowe, A.D., Kayumov, L.,
Pandi-Perumal, S.R., Parry, B., Cardinali, D.P., 2006. Melatonin in
mood disorders. World Journal of Biological Psychiatry 7,
138–151.
Strogatz, S.H., Kronauer, R.E., Czeisler, C.A., 1986. Circadian regulation dominates homeostatic control of sleep length and prior
wake length in humans. Sleep 9, 353–364.
214
V. Srinivasan et al. / Psychiatry Research 165 (2009) 201–214
Terman, J.S., Terman, M., Lo, E.S., Cooper, T.B., 2001. Circadian time
of morning light administration and therapeutic response in winter
depression. Archives of General Psychiatry 58, 69–75.
Thompson, C., Childs, P.A., Martin, N.J., Rodin, I., Smythe, P.J.,
1997. Effects of morning phototherapy on circadian markers in
seasonal affective disorder. British Journal of Psychiatry 170,
431–435.
Trivedi, M.H., Rush, A.J., Armitage, R., Gullion, C.M., Grannemann,
B.D., Orsulak, P.J., Roffwarg, H.P., 1999. Effects of fluoxetine on
the polysomnogram in outpatients with major depression. Neuropsychopharmacology 20, 447–459.
Tuunainen, A., Kripke, D.F., Elliott, J.A., Assmus, J.D., Rex, K.M.,
Klauber, M.R., Langer, R.D., 2002. Depression and endogenous
melatonin in postmenopausal women. Journal of Affective Disorders 69, 149–158.
Tzischinsky, O., Shlitner, A., Lavie, P., 1993. The association between
the nocturnal sleep gate and nocturnal onset of urinary 6-sulfatoxymelatonin. Journal of Biological Rhythms 8, 199–209.
Venkoba rao, A., Parvathi Devi, S., Srinivasan, V., 1983. Urinary
melatonin in depression. Indian Journal of Psychiatry 25, 167–172.
Wehr, T., Goodwin, F.K., 1979. Tricyclics modulate frequency of
mood cycles. Chronobiologia 6, 377–385.
Wehr, T.A., Wirz-Justice, A., 1982. Circadian rhythm mechanisms in
affective illness and in antidepressant drug action. Pharmacopsychiatria. 15, 31–39.
Wehr, T.A., Duncan Jr., W.C., Sher, L., Aeschbach, D., Schwartz, P.J.,
Turner, E.H., Postolache, T.T., Rosenthal, N.E., 2001. A circadian
signal of change of season in patients with seasonal affective
disorder. Archives of General Psychiatry 58, 1108–1114.
Wetterberg, L., 1979. Clinical importance of melatonin. Progress in
Brain Research 52, 539–547.
Wiley, J.L., Dance, M.E., Balster, R.L., 1998. Preclinical evaluation of
the reinforcing and discriminative stimulus effects of agomelatine
(S-20098), a melatonin agonist. Psychopharmacology (Berlin)
140, 503–509.
Wingard, D.L., Berkman, L.F., 1983. Mortality risk associated with
sleeping patterns among adults. Sleep 6, 102–107.
Wirz-Justice, A., Graw, P., Krauchi, K., Sarrafzadeh, A., English, J.,
Arendt, J., Sand, L., 1996. ‘Natural’ light treatment of seasonal
affective disorder. Journal of Affective Disorders 37, 109–120.
Yous, S., Andrieux, J., Howell, H.E., Morgan, P.J., Renard, P., Pfeiffer,
B., Lesieur, D., Guardiola-Lemaitre, B., 1992. Novel naphthalenic
ligands with high affinity for the melatonin receptor. Journal of
Medical Chemistry 35, 1484–1486.
Zee, P.C., Manthena, P., 2007. The brain's master circadian clock:
implications and opportunities for therapy of sleep disorders. Sleep
Medicine Reviews 11, 59–70.
Zhdanova, I.V., Tucci, V., 2003. Melatonin circadian rhythms and
sleep. Current Treatments and Options in Neurology 5, 225–229.
Zupancic, M., Guilleminault, C., 2006. Agomelatine: a preliminary
review of a new antidepressant. CNS Drugs 20, 981–992.